CARIPRAZINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H32Cl2N4O
Molecular Weight	427.411
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C3=CC=CC(Cl)=C3Cl)CC1

InChI

InChIKey=KPWSJANDNDDRMB-QAQDUYKDSA-N

InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17-

HIDE SMILES / InChI

Molecular Formula	C21H32Cl2N4O
Molecular Weight	427.411
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26956157

Cariprazine is an antipsychotic approved by FDA for the treatment of schizophrenia and bipolar I disorder. The drug has a unique clinical action which is explained by its ability to act on dopamine D3 receptors. Pharmacology studies revealed that cariprazine is a dual partial agonist of dopamine D2 and D3 receptors as well as serotonin 5HT1a, 2a and 2b receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26956157	Partial Agonist 297	0.49 nM [Ki]
Dopamine D3 receptor 97 Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26956157	Partial Agonist 297	0.085 nM [Ki]
Serotonin 1a (5-HT1a) receptor 177 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26956157	Partial Agonist 297	2.6 nM [Ki]
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26956157	Antagonist 2849	18.8 nM [Ki]
Serotonin 2b (5-HT2b) receptor 60 Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26956157	Antagonist 2849	0.58 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 305 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	Primary		Approved 8583	VRAYLAR Approved Use VRAYLAR is indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. Launch Date 2015
Bipolar I disorder 19 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	Primary		Approved 8583	VRAYLAR Approved Use VRAYLAR is indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. Launch Date 2015

C_max

Value	Dose	Analyte	Population
10.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	3 mg 1 times / day multiple, oral dose: 3 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
22.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
28.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	9 mg 1 times / day multiple, oral dose: 9 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
156 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	3 mg 1 times / day multiple, oral dose: 3 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
358 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
466 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	9 mg 1 times / day multiple, oral dose: 9 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
68.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	3 mg 1 times / day multiple, oral dose: 3 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
44.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
31.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26834462	9 mg 1 times / day multiple, oral dose: 9 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
9% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204370s006lbl.pdf	unknown, unknown		CARIPRAZINE HYDROCHLORIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
5.7 mg 1 times / day steady, oral Recommended Dose: 5.7 mg, 1 times / day Route: oral Route: steady Dose: 5.7 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28478771	unhealthy, 39.1 years Health Status: unhealthy Age Group: 39.1 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/28478771	Disc. AE: Schizophrenia aggravated, Psychotic disorder... AEs leading to discontinuation/dose reduction: Schizophrenia aggravated (2.7%) Psychotic disorder (2%) ALT increased (2 patients) AST increased (2 patients) Bilirubin increased (1 patient) Akathisia (0.9%) Extrapyramidal disorder (0.3%) Restlessness (0.2%) Dystonia (0.2%) Parkinsonism (0.2%) Salivary hypersecretion (0.2%) Tremor (0.2%) Musculoskeletal stiffness (0.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/28478771
12 mg 1 times / day steady, oral Highest studied dose Dose: 12 mg, 1 times / day Route: oral Route: steady Dose: 12 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25562205	unhealthy, 41,2 years (range: 18-65 years) Health Status: unhealthy Age Group: 41,2 years (range: 18-65 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25562205	Disc. AE: Akathisia... AEs leading to discontinuation/dose reduction: Akathisia Sources: https://pubmed.ncbi.nlm.nih.gov/25562205
6 mg 1 times / day steady, oral Recommended Dose: 6 mg, 1 times / day Route: oral Route: steady Dose: 6 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	unhealthy, Elderly Health Status: unhealthy Age Group: Elderly Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	Disc. AE: Akathisia... AEs leading to discontinuation/dose reduction: Akathisia (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 CYP3A5 136 P-gp 1741 BCRP 910 OATP1B1 1079 OATP1B3 961 OAT3 747 OCT2 779 CYP2A6 879 CYP2E1 1060	CYP3A 220 P-gp 2052 BCRP 697 OATP1B1 503 OATP1B3 435 OAT3 391 OCT2 434	CYP1A2 832

Drug as perpetrator

Target	Modality	Activity	Metabolite
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	inconclusive
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
CYP3A5 201	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
CYP3A5 201	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
CYP3A5 201	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	weak
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	weak
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	weak
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	weak
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	weak
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	weak
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000LBL.pdf#page=22 Page: 22.0	weak

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DCAR 2
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=54 Page: 54.0	no	DDCAR 2
CYP3A 220	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=29 Page: 29.0	yes		yes (co-administration study) Comment: In vivo data showed that a strong CYP3A4 inhibitor (i.e., ketoconazole) increased the total effective exposure after cariprazine administration by about 100% (study RGH-PK-07). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=29 Page: 29.0
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=29 Page: 29.0	yes		yes (pharmacogenomic study) Comment: Based on a population PK analysis, steady-state AUC0-24 of DDCAR in poor metabolizers of CYP2D6 was about 16% higher than in extensive metabolizers. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000ClinPharmR.pdf#page=29 Page: 29.0

Tox targets

Target	Modality	Metabolite
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000PharmR.pdf#page=473 Page: 473.0
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000PharmR.pdf#page=473 Page: 473.0	DCAR 2
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000PharmR.pdf#page=473 Page: 473.0	DDCAR 2

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:90933	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:90933
ChemicalBook	CB22563442	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB22563442
MolPort	MolPort-039-139-594	https://www.molport.com/shop/molecule-link/MolPort-039-139-594
ZINC	ZINC000100907004	http://zinc15.docking.org/substances/ZINC000100907004

PubMed

Title	Date	PubMed
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.	2010 Apr	20093397
Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.	2010 Jul	20571978
Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.	2012 May 15	22537450
Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.	2013 Feb	23320989
Cariprazine: First Global Approval.	2015 Nov	26510944

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is from 1.5 mg to 6 mg/day (schizophrenia) and 3 mg to 6 mg/day (bipolar mania).

Route of Administration: Oral

In Vitro Use Guide

Rat striatal and hippocampal membrane preparation were treated with a range of cariprazine concentrations from 0.1 nM to 0.1 mM to study [35S]GTPgammaS binding.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:39:26 GMT 2025` Edited by `admin` on `Mon Mar 31 20:39:26 GMT 2025`
Record UNII	F6RJL8B278
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GED-129

Preferred Name

English

CARIPRAZINE

Official Name

English

CARIPRAZINE [USAN]

Common Name

English

FRI-7000188

Common Name

English

cariprazine [INN]

Common Name

English

CARIPRAZINE [MI]

Common Name

English

3-(TRANS-4-(2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)ETHYL)CYCLOHEXYL)-1,1-DIMETHYLUREA

Systematic Name

English

MP-214

Code

English

RGH-188

Code

English

Cariprazine [WHO-DD]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175430